Skip to main content

SAB Biotherapeutics, Inc.

SABS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001833214

No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.

Other share classesSABSW

13F holders, Q4 2023

Institutional positions in SAB Biotherapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
42
+9 vs. Q3 2023
Shares held
35.6M
+32.3M (+973.1%) vs. Q3 2023
Total value
$24.5M
+$22.4M (+1,069.5%) vs. Q3 2023
New holders
14
6 more added
Sold out
5
4 more reduced

1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting SABS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2023: 42 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 1 institutionQ4 2021: 34 institutionsQ1 2022: 27 institutionsQ2 2022: 37 institutionsQ3 2022: 40 institutionsQ4 2022: 38 institutionsQ1 2023: 39 institutionsQ2 2023: 38 institutionsQ3 2023: 34 institutionsQ4 2023: 42 institutionsQ1 2024: 24 institutionsQ2 2024: 22 institutionsQ3 2024: 25 institutionsQ4 2024: 25 institutionsQ1 2025: 26 institutionsQ2 2025: 25 institutionsQ3 2025: 34 institutionsQ4 2025: 48 institutionsQ1 2026: 76 institutionsQ2 2026: 87 institutions
Value heldQ4 2023: $24.5M
Q1 2021: $0Q2 2021: $0Q3 2021: $605.0KQ4 2021: $25.4MQ1 2022: $6.71MQ2 2022: $4.45MQ3 2022: $2.32MQ4 2022: $2.42MQ1 2023: $1.71MQ2 2023: $3.28MQ3 2023: $2.41MQ4 2023: $24.5MQ1 2024: $15.2MQ2 2024: $9.69MQ3 2024: $8.48MQ4 2024: $10.1MQ1 2025: $2.99MQ2 2025: $3.37MQ3 2025: $56.3MQ4 2025: $135.9MQ1 2026: $265.0MQ2 2026: $266.8M
Institutions holding SABS and their total value by quarter
QuarterHoldersValue
Q2 202687$266.8M
Q1 202676$265.0M
Q4 202548$135.9M
Q3 202534$56.3M
Q2 202525$3.37M
Q1 202526$2.99M
Q4 202425$10.1M
Q3 202425$8.48M
Q2 202422$9.69M
Q1 202424$15.2M
Q4 202342$24.5M
Q3 202334$2.41M
Q2 202338$3.28M
Q1 202339$1.71M
Q4 202238$2.42M
Q3 202240$2.32M
Q2 202237$4.45M
Q1 202227$6.71M
Q4 202134$25.4M
Q3 20211$605.0K
Q2 20210$0
Q1 20210$0

Institutions, Q4 2023

Shares, value and share of portfolio for each institution holding SAB Biotherapeutics, Inc.; share changes are against Q3 2023.

Institutions holding SABS in Q4 2023
InstitutionSharesValue% of portfolioChange in sharesAction
BVF Inc9,178,282$6.31M0.16%+9,178,282New
RTW Investments, LP9,178,282$6.31M0.10%+9,178,282New
Marshall Wace, LLP4,585,282$3.16M0.01%+4,585,282New
Sessa Capital IM, L.P.4,584,571$3.15M0.15%+4,584,571New
Ra Capital Management, L.P.2,374,081$1.63M0.03%+2,374,081New
Commodore Capital LP1,831,746$1.26M0.11%+1,831,746New
Vanguard Group Inc996,132$684.8K0.00%+19,194+2.0%Added
First PREMIER Bank807,535$555.0K0.16%00.0%Unchanged
Pathstone Holdings, LLC506,513$348.2K0.00%+506,513New
Geode Capital Management, LLC356,364$245.1K0.00%00.0%Unchanged
First Manhattan Co277,777$191.0K0.00%00.0%Unchanged
Institutional & Family Asset Management, LLC192,027$132.0K0.02%00.0%Unchanged
Kestra Advisory Services, LLC88,000$60.5K0.00%+67,000+319.0%Added
State Street Corp81,241$55.9K0.00%00.0%Unchanged
Mariner, LLC69,000$47.4K0.00%00.0%Unchanged
Renaissance Technologies LLC63,100$43.0K0.00%+5,000+8.6%Added
BlackRock Inc.52,643$36.2K0.00%00.0%Unchanged
Peapack Gladstone Financial Corp52,296$36.0K0.00%00.0%Unchanged
Silver Oak Securities, Inc51,891$35.7K0.00%+51,891New
Creative Planning47,518$32.7K0.00%00.0%Unchanged
Advisor Group Holdings, Inc.46,373$31.9K0.00%−300−0.6%Reduced
Northern Trust Corp44,476$30.6K0.00%00.0%Unchanged
Citadel Advisors LLC16,719$11.5K0.00%+16,719New
Charles Schwab Investment Management Inc16,238$11.2K0.00%00.0%Unchanged
Tower Research Capital LLC (TRC)15,235$10.5K0.00%+295+2.0%Added
Nadler Financial Group, Inc.13,750$9.45K0.00%00.0%Unchanged
Commonwealth Equity Services, LLC12,823$9.00K0.00%+12,823New
Morgan Stanley11,506$7.91K0.00%−3,900−25.3%Reduced
1st Source Bank10,000$6.88K0.00%00.0%Unchanged
Baird Financial Group, Inc.10,000$6.88K0.00%00.0%Unchanged
Elgethun Capital Management5,435$6.47K0.00%−4,500−45.3%Reduced
Spectrum Wealth Counsel, LLC5,030$3.46K0.00%+5,030New
LM Advisors LLC3,620$2.49K0.00%+3,620New
Gs Investments, Inc.2,000$1.38K0.00%00.0%Unchanged
JPMorgan Chase & Co951$6540.00%+24+2.6%Added
UBS Group AG500$3440.00%+500New
FMR LLC343$2360.00%00.0%Unchanged
Wells Fargo & Company294$2020.00%+26+9.7%Added
GWM Advisors LLC145$1000.00%00.0%Unchanged
Qube Research & Technologies Ltd69$470.00%00.0%Unchanged
Bank of America Corp54$380.00%+54New
Royal Bank of Canada68$00.00%−5,026−98.7%Reduced
HighTower Advisors, LLC0$00.00%−73,470−100.0%Sold out
Brookstone Capital Management0$00.00%−21,755−100.0%Sold out
LGL Partners, LLC0$00.00%−23,000−100.0%Sold out
Strategic Financial Concepts, LLC0$00.00%−15,027−100.0%Sold out
Harbour Investments, Inc.0$00.00%−500−100.0%Sold out
Pathstone Family Office, LLC––––Not filed